Nucleome Therapeutics, a leading UK biotech firm that specialises in decoding the dark genome's non-coding DNA regions to develop precision medicines for autoimmune diseases like multiple sclerosis, lupus, and rheumatoid arthritis, purchase LTE research-grade autoclave to assist with research. Click to read more.